Le Lézard
Classified in: Health, Science and technology
Subjects: PLW, MAT

Ixtlan Bioscience Announces the Filing of New Patent for the Psilocybin Treatment of Alzheimer's Disease and Brain Pathologies


TEL AVIV, Israel, Dec. 21, 2021 /PRNewswire/ -- Ixtlan Bioscience, a biotech company focused on developing psilocybin-based treatment for Alzheimer's Disease and Brain Pathologies, has announced today the filing of a new Provisional Patent with the United States Patent and Trademark Office (USPTO) Application No. 63279349 ? named; Ixtlan AD Kit, which is a novel treatment for Alzheimer's and neuronal disorders. 

"We are pleased to announce this new provisional patent filing for Alzheimer's Disease and brain pathologies, which is very important for the development of our novel and proprietary Ixtlan AD Kit, for at-home treatment of patients suffering from Alzheimer's and other dementia diseases," commented Yehonatan Cavens, chief finance officer of Ixtlan Bioscience. 

Ixtlan AD kit comprises a unique assembly of tools the treatment of a variety of brain pathologies by micro-dosing of encapsulated 5HT2A receptor agonists, specifically psilocybin, along with a web-application and a physical product that have a triple purpose: a. providing a high-quality exercise at home to enhance the therapeutic potential of psilocybin micro-dosing, b. providing the progress report based on which the patient exercise can be corrected, and c. providing the extensive data that will be used to further improve the product.

"The invention generally pertains to compositions and methods for treating brain pathologies accompanied with cognitive and or motor impairments, dementia syndromes, such as Alzheimer's disease, stroke, multiple sclerosis and traumatic brain injury by micro-dosing administration of compositions comprising 5-HT2A receptor agonists", commented PhD. Ana Parabucki, head science of Ixtlan Bioscience. 

About Ixtlan Bioscience

Ixtlan Bioscience is an Israeli based biotech company devoted to defining and utilizing psilocybin micro-dosing to advance safe and accessible psilocybin medicine to slow down the progression of Alzheimer's and dementia diseases. Ixtlan Bioscience is focused on developing its novel and proprietary Ixtlan AD Kit, for the at-home treatment of patients suffering from Alzheimer's and dementia diseases.

For more information about Ixtlan

[email protected]/
https://www.ixtlanbioscience.com/
https://www.linkedin.com/company/ixtlan-bioscience/

SOURCE Ixtlan


These press releases may also interest you

at 10:21
Highlights of the Annual Results as of December 31, 2023: Revenue reached RMB2,155.6 millionGross profit amounted to RMB738.5 millionAdjusted non-IFRS net loss improved to RMB208.8 million, representing a significant turnaround from a negative...

at 10:17
The life insurance comparison site QuickQuote.com recently published a guide to accidental death and dismemberment (AD&D) insurance. It revealed that some plans cost only $4 a month and provide $100,000 in coverage....

at 10:15
Options Medical Weight Losstm, the nation's premier medical weight loss clinic and provider of medical weight loss solutions, is proud to announce its second clinic in the Metro Atlanta area at 3651 Peachtree Parkway, Suite B. The clinic cordially...

at 10:15
The "MRSA Drugs Market by MRSA Type, Drug Class, Disease Indication, Route of Administration, Distribution Channel, and Region 2024-2032" report has been added to ResearchAndMarkets.com's offering. The global MRSA drugs market size reached US$ 3.8...

at 10:15
Chartis, a comprehensive healthcare advisory firm, today announced that its line of business focused on helping medical staff services departments (MSSDs) transform to elevate performance will restore its former name?Greeley, A Chartis Company. It...

at 10:10
Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology and immunology, released annual...



News published on and distributed by: